Puyang Jin

Puyang JIN is a healthcare professional with extensive experience in the pharmaceutical and medical investment sectors. Currently, Puyang is employed at GL Capital Group since April 2022, where involvement includes a significant healthcare M&A transaction, specifically the privatization of SciClone Pharmaceuticals, valued at US$1.5 billion—marking it as a leading deal since 2021 in Greater China led by private equity funds. Prior roles include an internship at Lilly Asia Ventures focusing on innovative drug investment and positions at YunFeng Capital and PingAn Ventures, also centered on innovative drugs and advanced medical devices. Additionally, Puyang served as an intern in Strategic New Product Planning at Sanofi, assisting with product pipelines for rare blood diseases and immunity and inflammation. Educational credentials include a Master of Project Management from Northwestern University, a Bachelor of Science in Pharmacy from Fudan University, and a commerce exchange program at Waseda University.